Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 4
3(50.0%)
6Total
Phase 2(3)
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03042637Suspended

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

Role: lead

NCT00502268Phase 4Withdrawn

Vitamin D and Carboxy PTH Fragments in Coronary Calcification

Role: lead

NCT03106948Phase 2Unknown

Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis

Role: lead

NCT01922999Phase 2Unknown

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Role: lead

NCT00286403Phase 2Withdrawn

Vasodilators and Anti-Oxidant Therapy in Early ATN

Role: lead

NCT01073189Phase 4Withdrawn

Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury

Role: lead

NCT01028287Phase 4Completed

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

Role: lead

All 7 trials loaded